1
|
Russell-Smith TA, Brockbank J, Mamolo C, Knight C. Cost Effectiveness of Gemtuzumab Ozogamicin in the First-Line Treatment of Acute Myeloid Leukaemia in the UK. PHARMACOECONOMICS - OPEN 2021; 5:677-691. [PMID: 34181204 PMCID: PMC8611158 DOI: 10.1007/s41669-021-00278-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Accepted: 05/31/2021] [Indexed: 06/13/2023]
Abstract
BACKGROUND AND OBJECTIVE The phase III ALFA-0701 study demonstrated the efficacy and safety of gemtuzumab ozogamicin (GO) versus standard of care (SOC) chemotherapy (daunorubicin and cytarabine) for the treatment of adult patients with de novo CD33+ acute myeloid leukaemia (AML). This study analysed the cost-effectiveness of GO from the perspective of the UK health care payer. METHODS A cohort state-transition model was developed to estimate direct health care costs and quality-adjusted life-years (QALYs) over a lifetime time horizon from AML diagnosis to death using monthly cycles. Data on complete remission, overall survival, relapse-free survival (RFS), haematopoietic stem-cell transplantation, and adverse events for GO plus SOC versus SOC were obtained from the ALFA-0701 study. Overall survival and RFS were extrapolated beyond the trial horizon using mixture cure models. Unit costs were obtained from standard national sources. Utilities were identified in a systematic literature review. Costs and outcomes were discounted at 3.5%. Analyses were performed for the base-case population, excluding patients with an unfavourable cytogenetic profile, and the overall population. RESULTS For the base-case and overall populations respectively, incremental per-patient costs (£13,456 and £14,773) and QALYs (0.99 and 0.68) for GO plus SOC versus SOC resulted in incremental cost-effectiveness ratios (ICERs) of £13,561 and £21,819 per QALY gained. The mean probabilistic ICERs were £14,217 and £23,245, respectively. Univariate sensitivity analyses supported the robustness of the results. CONCLUSIONS The ICERs for both populations met NICE's £20,000-£30,000 willingness-to-pay threshold for medicines and supported the current approval for GO.
Collapse
Affiliation(s)
| | - James Brockbank
- Department of Health Economics, RTI Health Solutions, Manchester, UK
| | | | | |
Collapse
|
2
|
Hu H, Wang L, Li C, Ge W, Xia J. An improved method for the effect estimation of the intermediate event on the outcome based on the susceptible pre-identification. BMC Med Res Methodol 2021; 21:192. [PMID: 34548029 PMCID: PMC8454140 DOI: 10.1186/s12874-021-01378-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2021] [Accepted: 08/24/2021] [Indexed: 11/17/2022] Open
Abstract
Background In follow-up studies, the occurrence of the intermediate event may influence the risk of the outcome of interest. Existing methods estimate the effect of the intermediate event by including a time-varying covariate in the outcome model. However, the insusceptible fraction to the intermediate event in the study population has not been considered in the literature, leading to effect estimation bias due to the inaccurate dataset. Methods In this paper, we propose a new effect estimation method, in which the susceptible subpopulation is identified firstly so that the estimation could be conducted in the right population. Then, the effect is estimated via the extended Cox regression and landmark methods in the identified susceptible subpopulation. For susceptibility identification, patients with observed intermediate event time are classified as susceptible. Based on the mixture cure model fitted the incidence and time of the intermediate event, the susceptibility of the patient with censored intermediate event time is predicted by the residual intermediate event time imputation. The effect estimation performance of the new method was investigated in various scenarios via Monte-Carlo simulations with the performance of existing methods serving as the comparison. The application of the proposed method to mycosis fungoides data has been reported as an example. Results The simulation results show that the estimation bias of the proposed method is smaller than that of the existing methods, especially in the case of a large insusceptible fraction. The results hold for small sample sizes. Besides, the estimation bias of the new method decreases with the increase of the covariates, especially continuous covariates, in the mixture cure model. The heterogeneity of the effect of covariates on the outcome in the insusceptible and susceptible subpopulation, as well as the landmark time, does not affect the estimation performance of the new method. Conclusions Based on the pre-identification of the susceptible, the proposed new method could improve the effect estimation accuracy of the intermediate event on the outcome when there is an insusceptible fraction to the intermediate event in the study population. Supplementary Information The online version contains supplementary material available at 10.1186/s12874-021-01378-8.
Collapse
Affiliation(s)
- Haixia Hu
- Department of Health Statistics, Faculty of Preventive Medicine, Air Force Medical University, No.169 Changle West Road, Xi'an, 710032, Shaanxi, China
| | - Ling Wang
- Department of Health Statistics, Faculty of Preventive Medicine, Air Force Medical University, No.169 Changle West Road, Xi'an, 710032, Shaanxi, China
| | - Chen Li
- Department of Health Statistics, Faculty of Preventive Medicine, Air Force Medical University, No.169 Changle West Road, Xi'an, 710032, Shaanxi, China
| | - Wei Ge
- Department of Health Statistics, Faculty of Preventive Medicine, Air Force Medical University, No.169 Changle West Road, Xi'an, 710032, Shaanxi, China
| | - Jielai Xia
- Department of Health Statistics, Faculty of Preventive Medicine, Air Force Medical University, No.169 Changle West Road, Xi'an, 710032, Shaanxi, China.
| |
Collapse
|
3
|
Felizzi F, Paracha N, Pöhlmann J, Ray J. Mixture Cure Models in Oncology: A Tutorial and Practical Guidance. PHARMACOECONOMICS - OPEN 2021; 5:143-155. [PMID: 33638063 PMCID: PMC8160049 DOI: 10.1007/s41669-021-00260-z] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 02/07/2021] [Indexed: 05/10/2023]
Abstract
Novel cancer therapies are associated with survival patterns that differ from established therapies, which may include survival curves that plateau after a certain follow-up time point. A fraction of the patient population is then considered statistically cured and subject to the same mortality experience as the cancer-free general population. Mixture cure models have been developed to account for this characteristic. As compared to standard survival analysis, mixture cure models can often lead to profoundly different estimates of long-term survival, required for health economic evaluations. This tutorial is designed as a practical introduction to mixture cure models. Step-by-step instructions are provided for the entire implementation workflow, i.e., from gathering and combining data from different sources to fitting models using maximum likelihood estimation and model results interpretation. Two mixture cure models were developed to illustrate (1) an "uninformed" approach where the cure fraction is estimated from trial data and (2) an "informed" approach where the cure fraction is obtained from an external source (e.g., real-world data) used as an input to the model. These models were implemented in the statistical software R, with the freely available code on GitHub. The cure fraction can be estimated as an output from ("uninformed" approach) or used as an input to ("informed" approach) a mixture cure model. Mixture cure models suggest presumed estimates of long-term survival proportions, especially in instances where some fraction of patients is expected to be statistically cured. While this type of model may initially seem complex, it is straightforward to use and interpret. Mixture cure models have the potential to improve the accuracy of survival estimates for treatments associated with statistical cure, and the present tutorial outlines the interpretation and implementation of mixture cure models in R. This type of model will likely become more widely used in health economic analyses as novel cancer therapies enter the market.
Collapse
Affiliation(s)
- Federico Felizzi
- Value and Access and Commercial Development, Novartis Pharma AG, Fabrikstrasse 2, 4056, Basel, Switzerland.
| | - Noman Paracha
- Market Access Oncology, Bayer AG, Basel, Switzerland
| | | | - Joshua Ray
- HTA Evidence Group, Global Access Center of Excellence, F. Hoffmann-La Roche, Basel, Switzerland
| |
Collapse
|
4
|
Muresan B, Mamolo C, Cappelleri JC, Mokgokong R, Palaka A, Soikkeli F, Heeg B. Comparing cure rates for gemtuzumab ozogamicin plus standard chemotherapy vs standard chemotherapy alone in acute myeloid leukemia patients. Future Oncol 2021; 17:2883-2892. [PMID: 33858190 DOI: 10.2217/fon-2020-1287] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Aim: Assess the suitability of standard parametric, piecewise and mixture cure models (MCMs) for modeling long-term survival of acute myeloid leukemia patients achieving remission following treatment with gemtuzumab ozogamicin (GO) + standard chemotherapy (SC) or SC alone. MCMs can model survival data comprising of statistically cured (patients in long-term remission) and uncured patients. Materials & methods: Models were fit to patient-level data corresponding to individual treatment arms. Results: Visual inspection showed that MCMs fit the clinical data best. Survival modeling with MCMs showed that treatment with GO + SC versus SC alone results in higher statistical cure rates for event-free survival (rates: 26-35% vs 21-23%) and overall survival (rates: 48-52% vs 38-44%). Conclusion: MCMs are well suited to modeling long-term survival in acute myeloid leukemia patients. Clinical trial registration: NCT00927498 (ClinicalTrials.gov).
Collapse
Affiliation(s)
| | | | | | | | | | | | - Bart Heeg
- Ingress Health, Rotterdam, 3012, The Netherlands
| |
Collapse
|
5
|
Pértega-Díaz S, Balboa-Barreiro V, Seijo-Bestilleiro R, González-Martín C, Pardeiro-Pértega R, Yáñez-González-Dopeso L, García-Rodríguez T, Seoane-Pillado T. Characterisation of long-term cancer survivors and application of statistical cure models: a protocol for an observational follow-up study in patients with colorectal cancer. BMC Public Health 2020; 20:1738. [PMID: 33203431 PMCID: PMC7672896 DOI: 10.1186/s12889-020-09807-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2020] [Accepted: 10/30/2020] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Improved colorectal cancer (CRC) survival rates have been reported over the last years, with more than half of these patients surviving more than 5 years after the initial diagnosis. Better understanding these so-called long-term survivors could be very useful to further improve their prognosis as well as to detect other problems that may cause a significant deterioration in their health-related quality of life (HRQoL). Cure models provide novel statistical tools to better estimate the long-term survival rate for cancer and to identify characteristics that are differentially associated with a short or long-term prognosis. The aim of this study will be to investigate the long-term prognosis of CRC patients, characterise long-term CRC survivors and their HRQoL, and demonstrate the utility of statistical cure models to analyse survival and other associated factors in these patients. METHODS This is a single-centre, ambispective, observational follow-up study in a cohort of n = 1945 patients with CRC diagnosed between 2006 and 2013. A HRQoL sub-study will be performed in the survivors of a subset of n = 485 CRC patients for which baseline HRQoL data from the time of their diagnosis is already available. Information obtained from interviews and the clinical records for each patient in the cohort is already available in a computerised database from previous studies. This data includes sociodemographic characteristics, family history of cancer, comorbidities, perceived symptoms, tumour characteristics at diagnosis, type of treatment, and diagnosis and treatment delay intervals. For the follow-up, information regarding local recurrences, development of metastases, new tumours, and mortality will be updated using hospital records. The HRQoL for long-term survivors will be assessed with the EORTC QLQ-C30 and QLQ-CR29 questionnaires. An analysis of global and specific survival (competitive risk models) will be performed. Relative survival will be estimated and mixture cure models will be applied. Finally, HRQoL will be analysed through multivariate regression models. DISCUSSION We expect the results from this study to help us to more accurately determine the long-term survival of CRC, identify the needs and clinical situation of long-term CRC survivors, and could be used to propose new models of care for the follow-up of CRC patients.
Collapse
Affiliation(s)
- Sonia Pértega-Díaz
- Research Support Unit, Nursing and Healthcare Research Group, Rheumatology and Health Research Group, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), As Xubias, Hotel de Pacientes 7ª Planta, 15006, A Coruña, Spain.
| | - Vanesa Balboa-Barreiro
- Research Support Unit, Nursing and Healthcare Research Group, Rheumatology and Health Research Group, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), As Xubias, Hotel de Pacientes 7ª Planta, 15006, A Coruña, Spain
| | - Rocío Seijo-Bestilleiro
- Research Support Unit, Nursing and Healthcare Research Group, Rheumatology and Health Research Group, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), As Xubias, Hotel de Pacientes 7ª Planta, 15006, A Coruña, Spain
| | - Cristina González-Martín
- Research Support Unit, Nursing and Healthcare Research Group, Rheumatology and Health Research Group, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), As Xubias, Hotel de Pacientes 7ª Planta, 15006, A Coruña, Spain
| | - Remedios Pardeiro-Pértega
- Digestive Apparatus Service, Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, As Xubias, 15006, A Coruña, Spain
| | - Loreto Yáñez-González-Dopeso
- Digestive Apparatus Service, Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, As Xubias, 15006, A Coruña, Spain
| | - Teresa García-Rodríguez
- Digestive Apparatus Service, Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, As Xubias, 15006, A Coruña, Spain
| | - Teresa Seoane-Pillado
- Research Support Unit, Nursing and Healthcare Research Group, Rheumatology and Health Research Group, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), As Xubias, Hotel de Pacientes 7ª Planta, 15006, A Coruña, Spain
| |
Collapse
|
6
|
Nicolaie MA, Taylor JMG, Legrand C. Vertical modeling: analysis of competing risks data with a cure fraction. LIFETIME DATA ANALYSIS 2019; 25:1-25. [PMID: 29388073 DOI: 10.1007/s10985-018-9417-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/12/2015] [Accepted: 01/06/2018] [Indexed: 06/07/2023]
Abstract
In this paper, we extend the vertical modeling approach for the analysis of survival data with competing risks to incorporate a cure fraction in the population, that is, a proportion of the population for which none of the competing events can occur. The proposed method has three components: the proportion of cure, the risk of failure, irrespective of the cause, and the relative risk of a certain cause of failure, given a failure occurred. Covariates may affect each of these components. An appealing aspect of the method is that it is a natural extension to competing risks of the semi-parametric mixture cure model in ordinary survival analysis; thus, causes of failure are assigned only if a failure occurs. This contrasts with the existing mixture cure model for competing risks of Larson and Dinse, which conditions at the onset on the future status presumably attained. Regression parameter estimates are obtained using an EM-algorithm. The performance of the estimators is evaluated in a simulation study. The method is illustrated using a melanoma cancer data set.
Collapse
Affiliation(s)
- Mioara Alina Nicolaie
- Institute of Statistics, Biostatistics and Actuarial Sciences, Catholic University of Louvain, Voie du Roman Pays 20, bte L1.04.01, 1348, Louvain-la-Neuve, Belgium.
| | - Jeremy M G Taylor
- School of Public Health, University of Michigan, M4509 SPH II, 1415 Washington Heights, Ann Arbor, MI, 48109-2029, USA
| | - Catherine Legrand
- Institute of Statistics, Biostatistics and Actuarial Sciences, Catholic University of Louvain, Voie du Roman Pays 20, bte L1.04.01, 1348, Louvain-la-Neuve, Belgium
| |
Collapse
|